GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (MIL:1INCY) » Definitions » Cyclically Adjusted Book per Share

Incyte (MIL:1INCY) Cyclically Adjusted Book per Share : €10.20 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Incyte Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Incyte's adjusted book value per share for the three months ended in Mar. 2024 was €22.102. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €10.20 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Incyte's average Cyclically Adjusted Book Growth Rate was 31.40% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 43.70% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 59.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Incyte was 80.80% per year. The lowest was -56.10% per year. And the median was -0.85% per year.

As of today (2024-05-29), Incyte's current stock price is €49.12. Incyte's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €10.20. Incyte's Cyclically Adjusted PB Ratio of today is 4.82.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Incyte was 1233.83. The lowest was 4.66. And the median was 21.65.


Incyte Cyclically Adjusted Book per Share Historical Data

The historical data trend for Incyte's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Cyclically Adjusted Book per Share Chart

Incyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 9.15

Incyte Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 9.15 10.20

Competitive Comparison of Incyte's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Incyte's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Incyte's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Incyte's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Incyte's Cyclically Adjusted PB Ratio falls into.



Incyte Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Incyte's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=22.102/131.7762*131.7762
=22.102

Current CPI (Mar. 2024) = 131.7762.

Incyte Quarterly Data

Book Value per Share CPI Adj_Book
201406 -0.747 100.560 -0.979
201409 -0.412 100.428 -0.541
201412 -0.387 99.070 -0.515
201503 -0.221 99.621 -0.292
201506 0.273 100.684 0.357
201509 0.425 100.392 0.558
201512 0.842 99.792 1.112
201603 1.091 100.470 1.431
201606 1.407 101.688 1.823
201609 1.751 101.861 2.265
201612 2.106 101.863 2.724
201703 4.415 102.862 5.656
201706 4.444 103.349 5.666
201709 6.989 104.136 8.844
201712 6.522 104.011 8.263
201803 6.231 105.290 7.798
201806 6.984 106.317 8.656
201809 7.262 106.507 8.985
201812 7.938 105.998 9.868
201903 8.612 107.251 10.581
201906 9.256 108.070 11.286
201909 10.213 108.329 12.424
201912 10.818 108.420 13.148
202003 8.083 108.902 9.781
202006 9.547 108.767 11.567
202009 9.273 109.815 11.127
202012 9.779 109.897 11.726
202103 10.421 111.754 12.288
202106 11.055 114.631 12.708
202109 12.117 115.734 13.797
202112 15.091 117.630 16.906
202203 15.842 121.301 17.210
202206 17.417 125.017 18.359
202209 19.190 125.227 20.194
202212 18.521 125.222 19.490
202303 18.686 127.348 19.336
202306 19.592 128.729 20.056
202309 20.619 129.860 20.923
202312 21.219 129.419 21.605
202403 22.102 131.776 22.102

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Incyte  (MIL:1INCY) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Incyte's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=49.12/10.2
=4.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Incyte was 1233.83. The lowest was 4.66. And the median was 21.65.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Incyte Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Incyte's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Incyte (MIL:1INCY) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (MIL:1INCY) » Definitions » Cyclically Adjusted Book per Share
Traded in Other Exchanges
Address
1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Incyte (MIL:1INCY) Headlines

No Headlines